Dr. Guido Tricot, MD, PhD, Holden Cancer Center, University of Iowa Interview Date: July 12, 2013
Dr. Tricot discusses his investigation into ways of finding and treating the remaining cells (myeloma stem cells) that still can exist after typical treatments of transplantation and combination therapies. He discusses how immunotherapies will be used in combination with existing treatments and how with the upcoming ability to personalize treatment based on genetics, we may be able to separate out patients that need intensive treatment and those that can be cured without intensive treatment based on their myeloma's characteristics. He cites the most recent results from tandem transplantation protocols with a review of how therapies can be advanced beyond transplantation.
Dr. Tricot's most recent clinical studies focus on not only attacking myeloma cells but also the microenvironment that supports the survival and growth of myeloma cells. His work aims at finding treatments that are non-cross-resistant with current chemotherapy and therefore can eradicate the drug-resistant myeloma cells. His work on detailed genetics of myeloma cells should allow individualized therapies to ensure the greatest efficacy, while minimizing toxicity. Over the last 15 years, the median survival for patients newly diagnosed with myeloma has, in large part due to this work, increased from 2.5 to more than 10 years. The complete remission rate has increased from 5% to 80% and one third of all patients are still in complete remission at 10 years. He received his medical degree from Catholic University of Leuven and has been in practice for more than 20 years.
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
+1 800 709 1113